Articles by Ariel Jones
Pirtobrutinib, a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, showed promising efficacy in patients with ...
A fixed-duration combination of the first-generation Bruton tyrosine kinase (BTK) inhibitor ibrutinib and the ...
Second-line therapy comprising standard rituximab plus bendamustine and bortezomib was effective and well-tolerated as ...
The trial was conducted by Dr. Malin Hultcrantz and colleagues, and presented at the 2021 American Society of Hematology.
A phase II study presented at the 2021 Annual Meeting & Exposition of the American Society of Hematology, reported ...
The all-oral, once-daily, fixed-duration combination of ibrutinib and venetoclax demonstrated superior undetectable MRD ...
In the iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) study, researchers explored whether ...
These results were presented at the 2021 American Society of Hematology Annual Meeting.
A study presented during the 2021 ASCO Annual Meeting observed a significant correlation between race and being harmed ...
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.